Results 51 to 60 of about 25,910 (264)

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Personal Neoantigen Vaccines Induce Persistent Neoantigen-Specific Memory T Cell Responses and Epitope Spreading in High-Risk Melanoma Patients

, 2020
Cancer vaccines have long been envisioned as an effective approach to generate, amplify and diversify T cell responses against tumors. The recent availability of next-generation sequencing (NGS) has enabled the comprehensive identification of mutations ...
Leet, Donna
core   +2 more sources

Neoantigen-based cancer immunotherapy [PDF]

Annals of Translational Medicine, 2016
Emerging clinical evidence on the role of the antitumor activity of the immune system has generated great interest in immunotherapy in all cancer types. Recent clinical data clearly demonstrated that human tumor cells express antigenic peptides (epitopes) that can be recognized by autologous tumor-specific T cells and that enhancement of such immune ...
Bobisse, S., Foukas, P.G., Coukos, G., Harari, A.   +3 more
openaire   +4 more sources

Unveiling the immunological landscape: comprehensive characterization of neoantigen-reactive immune cells in neoantigen cancer vaccines [PDF]

Neoantigen-based cancer vaccine therapy represents a promising precision oncology strategy that targets unique tumor-specific mutations to elicit a robust immune response.
Xiaoling Li, Liping Hong, Hong Su, Xishan Hao, Peng Guo, Weijiang Liu   +5 more
core   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

Engineering Antigen Density on M13 Bacteriophage for Personalized Nanovaccine

Advanced Healthcare Materials, EarlyView.
Increasing antigen density on the phage capsid impacts phage uptake and antigen cross‐presentation by antigen‐presenting cells, leading to enhanced activation of antitumor CD8+ T cells in the draining lymph nodes. These activated CD8+ T cells subsequently recognize the antigen‐expressing tumors and mediate their specific cytotoxic killing, thereby ...
Shengnan Huang, Allison Madow, Jack Rudrum, Huaiyao Peng, Hao Nghi Luu, Peiyan Dong, Jifa Qi, Angela M. Belcher   +7 more
wiley   +1 more source

Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies

, 2022
Alternatives to conventional cancer treatments are highly sought after for high-risk malignancies that have a poor response to established treatment modalities.
Carson R. Reynolds, Mohit Jain, Aru Narendran, Son Tran   +3 more
core   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

The role of neoantigens in tumor immunotherapy

Biomedicine & Pharmacotherapy, 2022
Tumor neoantigens are aberrant polypeptides produced by tumor cells as a result of genomic mutations. They are also tumor-specific antigens (TSA). Neoantigens are more immunogenic than tumor-related antigens and do not induce autoimmunity. Based on the rapid development of bioinformatics and the continuous update of sequencing technology, cancer ...
Shengwen, Shang, Yongjie, Zhao, Kaiqiang, Qian, Yuexuan, Qin, Xinyi, Zhang, Tianyue, Li, Lidong, Shan, Meili, Wei, Jun, Xi, Bikui, Tang   +9 more
openaire   +2 more sources